Frontline Genomics talks to Ranga Sarangarajan about our AI guided GBM trials

March 10, 2017

BERG’s Chief Scientific Officer, Ranga Sarangarajan talks to Liz Harley at Frontline Genomics about our Phase I/II glioblastoma multiforme trials that are being guided by BERG’s AI platform. Full article can be viewed here: http://www.frontlinegenomics.com/opinion/10472/artificial-intelligence-drug-cancer-berg/

Recent news

November 26, 2018

Drugmakers embracing AI’s utility to uncover hidden opportunities in discovery

November 24, 2018

Drugmakers embracing AI’s utility to uncover hidden opportunities in discovery

November 20, 2018

Pharma companies put faith in AI for breakthroughs

November 18, 2018

The State of AI in Pharmaceutical Drug Development

October 22, 2018

Fortune.com: 3 Ways AI Is Changing Healthcare

October 10, 2018

STATNEWS.com: AI for drug development: Experts break down what’s possible — and what’s just hype